OmniAb SPAC Presentation Deck

ADVANCED PIPELINE DRIVING DIVERSIFIED REVENUE KEY INFORMATION ● ● ● Expanded to >55 active partners with whom we have active license agreements or who have an active program Significant active program growth since acquisition Royalty revenue expected to grow significantly with average royalty rates typically in the low- to mid-single digits Iterative improvements of antibody discovery engine expected to continue driving royalty rates and market share higher Long-term value of our business will be driven by downstream royalty payments 28 OmniAb

View entire presentation